Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Cost of Care

The ASCO Post Staff

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Collyar: What's In It for Patients?

Nov

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Collyar: What's In It for Patients?

Pancreatic Cancer Mild Duct Dilation May Serve as Early Indicator in High-Risk Patients

Preliminary Activity of LuPSMA-IT Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis

Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer

SABR May Be Comparable to Surgery for Early-Stage NSCLC

MD Anderson Launches 2.5 Billion Philanthropic Campaign